Experimental Model for Studies of Pneumococcal Colonization in Older Adults

Pneumococci are major contributors to morbidity and mortality globally, being a major cause of community-acquired pneumonia, with or without septicemia, and bacterial meningitis, especially after the introduction of the Hib vaccine globally (1). The ecological niche for pneumococci is regarded to be the nasopharynx of young and healthy children and has been shown to carry pneumococci in the upper respiratory tract in up to 60% of cases (2, 3). Pneumococcal colonization is believed to be a prerequisite for acquiring severe invasive pneumococcal diseases (IPD) (4). Young children and the elderly belong to the risk groups for getting IPD; hence, pneumococcal conjugated vaccines (PCVs) were introduced into childhood vaccination programs in many countries, leading to a dramatic decrease of IPD in vaccinated children (5–8). However, some studies have shown that nasopharyngeal colonization rates in children have remained the same after PCV introduction because of an increase of nonvaccine types, that is, serotype replacement with nonvaccine strains (7, 9).

Several studies show that nasopharyngeal colonization decreases with age and that it is lower in adults than in children (10). Also, it has been suggested that adults might be less susceptible to pneumococcal colonization. More knowledge is needed on why age influences colonization, which immune responses are evoked by pneumococcal colonization, especially in the elderly population, and to what extent a prior colonization might protect against recolonization. These issues are being addressed in this issue of the Journal in the study by Adler and colleagues (pp. 604–613) (11). Previous experimental model systems in humans with pneumococcal challenge have studied immune responses in younger adults (12), but here, Adler and colleagues are the first to challenge healthy older adults from 50 to 80 years of age, thus also including the risk group of the elderly above 65 years of age. In total, 64 adults were challenged with a pneumococcal strain of serotype 6B, originally isolated from the nasopharynx of a child (13). The authors determined colonization rates by culture of nasal washes and humoral immune responses by anticapsular and antiprotein IgG levels. They found that colonization could be successfully established in 39% of the adults, though higher in the age group of 50 to 59 years (47%) than in those greater than or equal to 70 years of age (21%), suggesting that this model can be used for studies of pneumococcal colonization in all age groups. The authors conclude that colonization rates are similar between younger and older adults, but a larger study might be needed to clarify this issue, especially because only 14 participants were included in the 70- to 80-year-old group. In addition, only one pneumococcal strain was used in the study, and we know that there might be differences between strains of different serotypes in, for example, the ability to colonize, the length of carriage, and the pathogenicity. Moreover, pneumococci interact with other microbes in the respiratory microbiota, both other bacteria and viruses, which might affect colonization rates, and it has been shown that heterogeneity in the nasopharyngeal microbiome promotes pneumococcal colonization (14). One can speculate that the elderly might have more frequently undergone antibiotic treatment and that this could have reduced the diversity of the bacterial microbiome of the upper respiratory tract, as has been suggested previously (15). The expression of specific receptors of the nasopharyngeal epithelium that recognize pneumococcal proteins important for bacterial adhesion may also differ between individuals and influence colonization rates. Previously it has been described that aging and chronic inflammation were associated with enhanced expression levels in the lungs of receptors such as the pIgR (polymeric immunoglobulin receptor) (16). pIgR has been shown to interact with pneumococcal proteins such as PspC (CbpA), and hence this increased interaction might promote pneumococcal adhesion to epithelial and endothelial cells and disease development (17, 18). The current study opens possibilities to address these questions in a larger human experimental study including more participants, other pneumococcal serotypes, and data on the microbial nasopharyngeal flora and individual immune responses.

Interestingly, they observed that prior vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV23) did not affect colonization rates in older adults. There are few data on the effect of vaccination during pregnancy and effects in infants. N Engl J Med 2020;383:426–439.
4. Sadoff J, De Paepe E, Haazen W, Ormoruyi E, Bastian AR, Comeaux C, et al. Safety and immunogenicity of the Ad26.RSV.preF investigational vaccine coadministered with an influenza vaccine in older adults. J Infect Dis online ahead of print] 26 Aug 2020; DOI: 10.1093/infdis/jiaa409.
5. PATH. RSV vaccine and mAb snapshot. Vaccine Resour Libr 2020. [updated 2020 Mar 26; accessed 2020 Sep 4]. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/.
6. Verdijk P, van der Plas JL, van Brummelen EMJ, Jeeninga RE, de Haan CAM, Roestenberg M, et al. First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial. Vaccine 2020;38:6088–6095.
7. McFarland EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous J, et al. Live-attenuated respiratory syncytial virus vaccine with M2-2 deletion and with small hydrophobic noncoding region is highly immunogenic in children. J Infect Dis 2020;221:2050–2059.
8. Belshé RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685–696.
9. Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health 2017;2:e367–e374.
PPV23 on colonization; however, some studies show that PCVs might confer short protection, whereas other studies do not see an effect on colonization rates after PCV introduction, such as in Sweden, because of a massive serotype replacement by nonvaccine serotypes (7). PPV23 and PCVs target only a limited number of the 100 pneumococcal capsular polysaccharides described so far, and hence they do not protect against the whole pneumococcal population circulating in the society. Thus, development of vaccines on the basis of conserved pneumococcal proteins has been suggested. Importantly, Adler and colleagues analyzed antibody levels against 27 pneumococcal proteins and observed increased anti-protein antibody levels to several pneumococcal proteins, such as the adhesin PspC, PspA, PsaA, PcpA, PsaA, and the pilus protein RrgA (19, 20), in participants that were colonized but not in the noncolonized group. Several of these proteins have been suggested as vaccine candidates in protein-based vaccines. Potentially, pneumococcal colonization might influence protection by evoking antibodies to these proteins in older adults, but this remains to be studied. Surprisingly, though, and also in contrast to what was found previously for younger adults, the authors did not observe an increase in the antibody response (IgG) to the 6B capsule after colonization and rather a drop in noncolonized participants. Moreover, a rechallenge was performed 1 year later on the 16 participants that showed a limited protection to reacquisition of the same pneumococcal strain as opposed to what has been found in younger adults. These findings are interesting but need to be confirmed in a larger study and by using other pneumococcal strains and serotypes because the antibody response might be influenced by the serotype.

Pneumococcal diseases are human specific and need to be studied in humans, if possible. This study in older adults with no adverse effects shows the potential of using this experimental model system in all age groups. This highly needed to explain mechanisms for carriage in different age groups. Possibly such models could also be used in vaccine studies and to analyze the efficacy of vaccines as a complement to large clinical studies of IPD.

Author disclosures are available with the text of this article at www.atsjournals.org.

Federico Iovino, Ph.D.
Department of Microbiology, Tumor and Cell Biology
Karolinska Institute
Stockholm, Sweden

Birgitta Henries-Normark, M.D., Ph.D.
Department of Microbiology, Tumor and Cell Biology
Karolinska Institute
Stockholm, Sweden

and
Karolinska University Hospital
Stockholm, Sweden

ORCID ID: 0000-0002-5429-4759 (B.H.-N.).

References

1. Murdoch DR, Howie SRC. The global burden of lower respiratory infections: making progress, but we need to do better. Lancet Infect Dis 2018;18:1162–1163.

2. Bosch AATM, van Houten MA, Bruin JP, Wijmenga-Monsuur AJ, Trzciński K, Bogaert D, et al. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine 2016;34:531–539.

3. Nunes S, Félix S, Valente C, Simões AS, Tavares DA, Almeida ST, et al. The impact of private use of PCV7 in 2009 and 2010 on serotypes and antimicrobial resistance of Streptococcus pneumoniae carried by young children in Portugal: comparison with data obtained since 1996 generating a 15-year study prior to PCV13 introduction. Vaccine 2016;34:1648–1656.

4. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect Dis 2004;4:144–154.

5. Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329–337.

6. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multistate, population-based surveillance. Lancet Infect Dis 2015;15:301–309.

7. Galanis I, Lindstrand A, Darenberg J, Brouwer S, Nannapaneni P, Sjöström K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J 2016;47:1208–1218.

8. Naucler P, Galanis I, Morfeldt E, Darenberg J, Ortvist Å, Henries-Normark B. Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations. Clin Infect Dis 2017;65:1780–1789.

9. Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M, et al. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden. Vaccine 2016;34:4565–4571.

10. Smith EL, Wheeler I, Adler H, Ferreira DM, Sá-Leão R, Abdullahi O, et al. Upper airways colonisation of Streptococcus pneumoniae in adults aged 60 years and older: a systematic review of prevalence and individual participant data meta-analysis of risk factors. J Infect 2020;1:540–548.

11. Adler H, German EL, Mitsi E, Nikolau E, Poiras J, Hales G, et al. Experimental human pneumococcal colonization in older adults is feasible and safe, not immunogenic. Am J Respir Crit Care Med 2021;203:604–613.

12. Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013;187:855–864.

13. Brouwer S, Norman M, Tängrot J, Galanis I, Sjöström K, Dagerhamm J, et al. Intraclonal variations among Streptococcus pneumoniae isolates influence the likelihood of invasive disease in children. J Infect Dis 2014;209:377–388.

14. Cremers AJ, Zomer AL, Gritzfeld JF, Ferwerda G, van Hijum SA, Ferreira DM, et al. The adult nasopharyngeal microbiome as a determinant of pneumococcal acquisition. Microbiome 2014;2:44.

15. Giarratano A, Green SE, Nicolau DP. Review of antimicrobial use and considerations in the elderly population. Clin Infect Dis 2018;13:657–667.

16. Boyd AR, Orihuela CJ. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis 2011;2:487–500.

17. Iovino F, Engelen-Lee JY, Brouwer M, van de Beek D, van der Ende A, Vals Seron M, et al. pIgR and PECAM–1 bind to pneumococcal adhesins RrgA and PspC mediating bacterial brain invasion. J Exp Med 2017;214:1619–1630.

18. Hinajosa E, Boyd AR, Orihuela CJ. Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J Infect Dis 2009;200:546–554.

19. Pathak A, Bergstrand J, Sander V, Spelmink L, Aschtgen MS, Muschiol S, et al. Factor H binding proteins protect division septa on encapsulated Streptococcus pneumoniae against complement C3b deposition and amplification. Nat Commun 2018;9:3398.

20. Nelson AL, Ries J, Bagnoli F, Dahlberg S, Falker S, Rounioja S, et al. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol 2007;66:329–340.